Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 trial of cytisine for the treatment of smoking cessation.

Trial Profile

A phase 3 trial of cytisine for the treatment of smoking cessation.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytisine (Primary)
  • Indications Smoking withdrawal
  • Focus Registrational; Therapeutic Use
  • Sponsors Achieve Life Sciences
  • Most Recent Events

    • 24 Oct 2019 According to an Achieve Life Sciences media release, the company plans to initiate the Phase 3 development program in 2020.
    • 24 Oct 2019 According to an Achieve Life Sciences media release, based on the ORCA-1 trial results, the future Phase 3 clinical trials are expected to utilize 3.0 mg TID dosing of cytisinicline.
    • 11 Jul 2018 According to an Achieve Life Sciences media release, the study is expected initiate in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top